Josep Piulats, MD, discussed the TRITON2 data and how rucaparib could shift treatment for these biomarker-specific patients with metastatic castration-resistant prostate cancer.
Original Article: Rucaparib Shows Encouraging Responses in BRCA+ mCRPC